# Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

> **NCT00885833** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Korean Society of Pediatric Hematology Oncology** · enrollment: 5 (estimated)

## Conditions studied

- Wiskott-Aldrich Syndrome

## Interventions

- **DRUG:** Fludarabine, Busulfan, Thymoglobulin

## Key facts

- **NCT ID:** NCT00885833
- **Lead sponsor:** The Korean Society of Pediatric Hematology Oncology
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885833, "Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00885833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*